## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG 1.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($466.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Rothblatt, United Therapeutics CEO, sells $3.8m in UTHR stock**
- Source: Investing.com | 20251209T200953 | Neutral | Relevance: 98%
-  Martine Rothblatt, CEO of United Therapeutics Corp (UTHR), sold 8,000 shares worth approximately $3.87 million between December 5 and December 8, 2025. Concurrently, Rothblatt exercised stock options to acquire 8,000 shares for $962,080. These transactions were part of a pre-arranged 10b5-1 trading plan. The company's financial health is rated excellent, with a robust market capitalization and positive analyst outlook despite a recent revenue miss.

**2. Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor**
- Source: GuruFocus | 20251210T000921 | Neutral | Relevance: 97%
-  United Therapeutics Corp Director Nilda Mesa sold 187 shares of the company on December 9, 2025, reducing her holdings to 5,286 shares. The company has seen 103 insider sells and no insider buys in the past year. United Therapeutics Corp is considered modestly overvalued with a price-to-GF-Value ratio of 1.28.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 14 ($11.47M) |
| Sells | 70 ($38.89M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $39M sold (70 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.1x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($38.9M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.1B |
| Beta | 0.86 |
| 52W Range | $266.98 - $492.62 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.1 |
| Current P/E | 18.0 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+1.0% over 5 days). Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 at 1.0% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.21), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.85% (CS: 47) | Neutral |
| RSI_14 | 63.0 | Neutral |
| MACD Histogram | -1.21 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.071x | Above |
| vs SMA200 | 1.386x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $488.51
- **Stop Loss:** $466.33 (4.5% risk)
- **Target:** $510.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 62
- **Position Value:** $30,287.62
- **Portfolio %:** 30.29%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*